Key facts
- This page summarizes David A. Socks's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2021, 17:31.
David A. Socks - 16 Aug 2021 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)
- Reporting relationship
- Director
- Issuer ticker
- PHAT
- Reported as of
- 16 Aug 2021
- Net transaction value
- -$562,538
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2021, 17:31:06 UTC
- Prior SEC filing
- 29 Jun 2021
- Next SEC filing
- 23 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Larry Miller, Attorney-in-Fact for David A. Socks
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David A. Socks filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 18 Aug 2021.
Change
- Previous filing in this sequence was filed on 29 Jun 2021.
- Current net transaction value: -$562,538.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHAT
transaction
Common Stock
Sale
- Transaction value
- $128,250
- Shares
- -4,209
- Change %
- -0.33%
- Price
- $30.47
- Shares after
- 1,261,137
- Date
- 16 Aug 2021
- Ownership
- David A. Socks 2013 Revocable Trust
- Footnotes
- F1, F2, F3
PHAT
transaction
Common Stock
Sale
- Transaction value
- $434,288
- Shares
- -13,791
- Change %
- -1.1%
- Price
- $31.49
- Shares after
- 1,247,346
- Date
- 16 Aug 2021
- Ownership
- David A. Socks 2013 Revocable Trust
- Footnotes
- F4
PHAT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 103
- Date
- 16 Aug 2021
- Ownership
- By 401(k)
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.98. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The total number of outstanding shares reflects an increase of 4,401 shares to correct an arithmetic error in the total number of shares initially reported on his Form 4 filed on November 9, 2020.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.80.The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.